19 hours ago For assistance with our program, please call our toll-free number Monday – Friday from 8:30 a.m. – 6:00 p.m. Eastern time: BI Cares Patient Assistance Program (includes a number of … >> Go To The Portal
Ridgefield, CT, April 2, 2013 – Boehringer Ingelheim Cares Foundation today announced the launch of its new website for its Patient Assistance Program (PAP) – a program that provides Boehringer Ingelheim medicines free of charge to eligible uninsured or underinsured patients who cannot afford them.
Human Health Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products. Section Overview Back Human Health
Contact Us Boehringer Ingelheim Boehringer Ingelheim About Us About Us At Boehringer Ingelheim we are driven by the desire to serve humankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity.
Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products. Section Overview Back Human Health Section Overview Heart Diseases Back Heart Diseases Go to Section Heart Failure Hypertension
The Boehringer Ingelheim Cares Foundation (BI Cares) is an independent nonprofit organization with a mission to strengthen the communities where our employees live and work by improving the health and well-being of people and animals.
If you have Medicare and you're having trouble paying for Jardiance, there's an assistance program available that you may qualify for. To find out more, visit the manufacturer's website or call 800-556-8317.
The TRADJENTA Savings Program—eligible patients pay as little as $10* per 30-, 60-, or 90-day supply (with maximum savings up to $150)
The cost for Jardiance oral tablet 10 mg is around $610 for a supply of 30 tablets, depending on the pharmacy you visit....Oral Tablet.QuantityPer unitPrice30$20.34$610.2290$20.13$1,811.65
Your actual cost or co-pay will depend on your insurance plan's drug coverage. Each plan is different and will determine your out-of-pocket cost. On average, 90%, or 9 out of 10 patients, will pay between $0–$40 per month for JARDIANCE, and the remaining 10% will pay an average of $227 per month.
The cost for Tradjenta oral tablet 5 mg is around $541 for a supply of 30 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
Can Tradjenta cause side effects related to the kidneys? No, Tradjenta isn't known to cause side effects related to the kidneys. It's important to note that people with diabetes have an increased risk of kidney problems. This is because, over time, high blood sugar levels can damage the kidneys.
Tradjenta is currently available as a brand-name medication. A generic version of Tradjenta, called linagliptin, has been approved by the Food and Drug Administration (FDA).
Jardiance is too expensive, especially if you have to pay out of pocket. To save money, you may want to talk to your doctor about three possibly cheaper alternatives: Victoza, Invokana and Invokamet.
If you are paying out of pocket, Jardiance is expensive. But it has more benefits and fewer drawbacks than less expensive medications. You can save money on Jardiance with a manufacturer savings card or patient assistance program. GoodRx also offers a coupon to lower the pill's monthly cost.
With Jardiance Savings Card, eligible patients can pay as little as $10 for a 1-3 month supply. Maximum savings is up to $175 per monthly prescription of Jardiance. Call 1-866-279-8990 for questions about the program.
Other alternatives to Jardiance.Glucophage (metformin)Januvia (sitagliptin)Victoza (liraglutide)Starlix (nateglinide)Actos (pioglitazone)Glyset (miglitol)
About Boehringer Ingelheim. The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
The PAP is one of the four core programs of Boehringer Ingelheim Cares Foundation.
As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
The portal was launched in response to BI’s desire to improve customer service, make its products even more accessible to those in need, and give patients and doctors more control over the process . Its launch aligns with the Foundation’s strategic goal to improve access to healthcare for the underserved.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
The US-based Boehringer Ingelheim Cares Foundation (BI Cares), an independent nonprofit organization, is making monetary donations and donating urgently needed medicines for patients through our non-governmental organization (NGO) partners. BI Cares added a new cause to its Matching Gifts Program to provide Boehringer Ingelheim US employees the opportunity to double the impact of their charitable giving to a fund being used to prevent the spread of and help those affected by COVID-19. The Foundation is also temporarily increasing the quantity or frequency of prescription medicine refills for all covered medicines to eligible US patients enrolled in its charitable Patient Assistance Program to assure patients they can remain adherent to the treatment they need for their medical conditions.
The Foundation is also temporarily increasing the quantity or frequency of prescription medicine refills for all covered medicines to eligible US patients enrolled in its charitable Patient Assistance Program to assure patients they can remain adherent to the treatment they need for their medical conditions.
The Boehringer Ingelheim Cares Foundation is not affiliated with any third party individual or organization that may charge patients a fee (s) to assist them in applying to our program or ordering refills through our program. These individuals or organizations are acting independently of the Boehringer Ingelheim Cares Foundation and do not have the Foundation’s consent.
The US-based Boehringer Ingelheim Cares Foundation (BI Cares), an independent nonprofit organization, is making monetary donations and donating urgently needed medicines for patients through our non-governmental organization (NGO) partners. BI Cares added a new cause to its Matching Gifts Program to provide Boehringer Ingelheim US employees the opportunity to double the impact of their charitable giving to a fund being used to prevent the spread of and help those affected by COVID-19. The Foundation is also temporarily increasing the quantity or frequency of prescription medicine refills for all covered medicines to eligible US patients enrolled in its charitable Patient Assistance Program to assure patients they can remain adherent to the treatment they need for their medical conditions.
The Foundation is also temporarily increasing the quantity or frequency of prescription medicine refills for all covered medicines to eligible US patients enrolled in its charitable Patient Assistance Program to assure patients they can remain adherent to the treatment they need for their medical conditions.
Boehringer Ingelheim has been family-owned since its foundation in 1885 and is one of the 20 largest companies in the pharmaceutical industry. Headquartered in Ingelheim, Germany, the company operates worldwide with 175 affiliates. Around 52,000 employees create value through innovation every day.
Please visit our global product overview if your local version does not exist yet.
The Boeh ringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
RIDGEFIELD, Conn., April 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Cares Foundation today announced the launch of its new website for its Patient Assistance Program (PAP) – a program that provides Boehringer Ingelheim medicines free of charge to eligible uninsured or underinsured patients who cannot afford them. The web portal will make the PAP easier to navigate and offer new features to benefit patients and physicians alike.
Learn how our cardiometabolic research and development gives patients hope and new treatments for a variety of heart, vascular, and metabolic diseases.
Find out why we are dedicated to improving the lives of patients with central nervous system (CNS) disorders and their caregivers.
Learn why we are focused on discovering and developing new therapies for chronic inflammatory and autoimmune diseases.
See how our scientists are developing innovative and personalized cancer treatment options.